Skip to main content
Top

Open Access 11-04-2025 | Bariatric Surgery | Original Research

Lights and Shadows of Bariatric Surgery: Insights from a Nationwide Administrative Database of People Living with Type 1 Diabetes and Obesity

Authors: Claire Carette, Claire Rives-Lange, Nicholas Shoung, Aurélie Phan, Elodie Torreton, Anne Dutour, Bruno Detournay, Sébastien Czernichow

Published in: Diabetes Therapy

Login to get access

Abstract

Introduction

The study aimed to describe the population of patients living with type 1 diabetes who had access to bariatric surgery (BS) in France, analyzing the changes in healthcare resource use and associated costs in the 3 years following this surgery.

Methods

An observational longitudinal study based on the French national health insurance database was conducted on all adult patients that underwent a first BS from 2015 to 2020. Cost analyses were conducted on a sub-population who underwent BS from 2016 to 2017 for sufficient observation time using a pre-post methodology.

Results

A total of 437 patients were identified as living with type 1 diabetes among the 234,077 patients who had undergone surgery over 6 years (2015–2020). The most frequently performed interventions were sleeve gastrectomy (n = 272; 62.2%) and gastric bypass (n = 154; 35.2%), with the majority of patients being women (77.8%) and an average age of 42.3 (± 12.0) years, consistent with the general population undergoing BS in France. While no significant differences were found in the overall healthcare costs when comparing the 3 years before and after BS, there was an increase in the frequency of biological measurements. Expenditures related to antidiabetic medications and insulin decreased significantly (p < 0.0001). The number of hospitalizations for severe hypoglycemia, coma, and ketoacidosis more than doubled in the 3 years following surgery compared with the period before (p = 0.04).

Conclusions

The risks of severe hypoglycemia or ketoacidosis in patients with type 1 diabetes undergoing BS remains a real concern and emphasizes the importance of involving the diabetologist in the operative decision with joint follow-up with the nutritionist.
Appendix
Available only for authorised users
Literature
1.
go back to reference Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9:776–85.CrossRefPubMed Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9:776–85.CrossRefPubMed
2.
go back to reference Maffeis C, Birkebaek NH, Konstantinova M, Schwandt A, Vazeou A, Casteels K, et al. Prevalence of underweight, overweight, and obesity in children and adolescents with type 1 diabetes: data from the international SWEET registry. Pediatr Diabetes. 2018;19:1211–20.CrossRefPubMed Maffeis C, Birkebaek NH, Konstantinova M, Schwandt A, Vazeou A, Casteels K, et al. Prevalence of underweight, overweight, and obesity in children and adolescents with type 1 diabetes: data from the international SWEET registry. Pediatr Diabetes. 2018;19:1211–20.CrossRefPubMed
3.
go back to reference De Keukelaere M, Fieuws S, Reynaert N, Vandoorne E, Kerckhove KV, Asscherickx W, et al. Evolution of body mass index in children with type 1 diabetes mellitus. Eur J Pediatr. 2018;177:1661–6.CrossRefPubMed De Keukelaere M, Fieuws S, Reynaert N, Vandoorne E, Kerckhove KV, Asscherickx W, et al. Evolution of body mass index in children with type 1 diabetes mellitus. Eur J Pediatr. 2018;177:1661–6.CrossRefPubMed
4.
go back to reference Fellinger P, Fuchs D, Wolf P, Heinze G, Luger A, Krebs M, et al. Overweight and obesity in type 1 diabetes equal those of the general population. Wien Klin Wochenschr. 2019;131:55–60.CrossRefPubMedPubMedCentral Fellinger P, Fuchs D, Wolf P, Heinze G, Luger A, Krebs M, et al. Overweight and obesity in type 1 diabetes equal those of the general population. Wien Klin Wochenschr. 2019;131:55–60.CrossRefPubMedPubMedCentral
5.
go back to reference Lavens A, Nobels F, De Block C, Oriot P, Verhaegen A, Chao S, et al. Effect of an integrated, multidisciplinary nationwide approach to type 1 diabetes care on metabolic outcomes: an observational real-world study. Diabetes Technol Ther. 2021;23:565–76.CrossRefPubMed Lavens A, Nobels F, De Block C, Oriot P, Verhaegen A, Chao S, et al. Effect of an integrated, multidisciplinary nationwide approach to type 1 diabetes care on metabolic outcomes: an observational real-world study. Diabetes Technol Ther. 2021;23:565–76.CrossRefPubMed
6.
go back to reference Fosse-Edorh S. Études Entred : un dispositif pour améliorer la connaissance de l’état de santé des personnes présentant un diabète en France – Premiers résultats de la troisième édition conduite en métropole en 2019/ENTRED studies: improving knowledge on the health status of people with diabetes in France – First results of the third edition conducted in metropolitan France, 2019. 2022 Fosse-Edorh S. Études Entred : un dispositif pour améliorer la connaissance de l’état de santé des personnes présentant un diabète en France – Premiers résultats de la troisième édition conduite en métropole en 2019/ENTRED studies: improving knowledge on the health status of people with diabetes in France – First results of the third edition conducted in metropolitan France, 2019. 2022
7.
go back to reference Conway B, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27:398–404.CrossRefPubMedPubMedCentral Conway B, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27:398–404.CrossRefPubMedPubMedCentral
8.
go back to reference Edqvist J, Rawshani A, Adiels M, Björck L, Lind M, Svensson A-M, et al. BMI, mortality, and cardiovascular outcomes in type 1 diabetes: findings against an obesity paradox. Diabetes Care. 2019;42:1297–304.CrossRefPubMed Edqvist J, Rawshani A, Adiels M, Björck L, Lind M, Svensson A-M, et al. BMI, mortality, and cardiovascular outcomes in type 1 diabetes: findings against an obesity paradox. Diabetes Care. 2019;42:1297–304.CrossRefPubMed
9.
go back to reference Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is “double diabetes” and what are the risks? Diabetologia. 2013;56:1462–70.CrossRefPubMedPubMedCentral Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is “double diabetes” and what are the risks? Diabetologia. 2013;56:1462–70.CrossRefPubMedPubMedCentral
10.
go back to reference Merger SR, Kerner W, Stadler M, Zeyfang A, Jehle P, Müller-Korbsch M, et al. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract. 2016;119:48–56.CrossRefPubMed Merger SR, Kerner W, Stadler M, Zeyfang A, Jehle P, Müller-Korbsch M, et al. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract. 2016;119:48–56.CrossRefPubMed
11.
go back to reference Snaith JR, Holmes-Walker DJ, Greenfield JR. Reducing type 1 diabetes mortality: role for adjunctive therapies? Trends Endocrinol Metab. 2020;31:150–64.CrossRefPubMed Snaith JR, Holmes-Walker DJ, Greenfield JR. Reducing type 1 diabetes mortality: role for adjunctive therapies? Trends Endocrinol Metab. 2020;31:150–64.CrossRefPubMed
12.
go back to reference Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes. Int J Obes (Lond). 2024;48:289–301.CrossRefPubMed Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes. Int J Obes (Lond). 2024;48:289–301.CrossRefPubMed
13.
go back to reference Tandon S, Ayis S, Hopkins D, Harding S, Stadler M. The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23:350–62.CrossRefPubMed Tandon S, Ayis S, Hopkins D, Harding S, Stadler M. The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2021;23:350–62.CrossRefPubMed
14.
go back to reference Thereaux J, Lesuffleur T, Czernichow S, Basdevant A, Msika S, Nocca D, et al. Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study. Lancet Diabetes Endocrinol. 2019;7:786–95.CrossRefPubMed Thereaux J, Lesuffleur T, Czernichow S, Basdevant A, Msika S, Nocca D, et al. Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study. Lancet Diabetes Endocrinol. 2019;7:786–95.CrossRefPubMed
15.
go back to reference Kirwan JP, Aminian A, Kashyap SR, Burguera B, Brethauer SA, Schauer PR. Bariatric surgery in obese patients with type 1 diabetes. Diabetes Care. 2016;39:941–8.CrossRefPubMedPubMedCentral Kirwan JP, Aminian A, Kashyap SR, Burguera B, Brethauer SA, Schauer PR. Bariatric surgery in obese patients with type 1 diabetes. Diabetes Care. 2016;39:941–8.CrossRefPubMedPubMedCentral
16.
go back to reference Parmar C, Appel S, Lee L, Ribeiro R, Sakran N, Pouwels S. Choice of bariatric surgery in patients with obesity and type 1 diabetes mellitus? An up-to-date systematic review. Obes Surg. 2022;32:3992–4006.CrossRefPubMed Parmar C, Appel S, Lee L, Ribeiro R, Sakran N, Pouwels S. Choice of bariatric surgery in patients with obesity and type 1 diabetes mellitus? An up-to-date systematic review. Obes Surg. 2022;32:3992–4006.CrossRefPubMed
17.
go back to reference Höskuldsdóttir G, Ekelund J, Miftaraj M, Wallenius V, Ottosson J, Näslund I, et al. Potential benefits and harms of gastric bypass surgery in obese individuals with type 1 diabetes: a nationwide, matched, observational cohort study. Diabetes Care. 2020;43:3079–85.CrossRefPubMed Höskuldsdóttir G, Ekelund J, Miftaraj M, Wallenius V, Ottosson J, Näslund I, et al. Potential benefits and harms of gastric bypass surgery in obese individuals with type 1 diabetes: a nationwide, matched, observational cohort study. Diabetes Care. 2020;43:3079–85.CrossRefPubMed
18.
go back to reference Brethauer SA, Aminian A, Rosenthal RJ, Kirwan JP, Kashyap SR, Schauer PR. Bariatric surgery improves the metabolic profile of morbidly obese patients with type 1 diabetes. Diabetes Care. 2014;37:e51-52.CrossRefPubMedPubMedCentral Brethauer SA, Aminian A, Rosenthal RJ, Kirwan JP, Kashyap SR, Schauer PR. Bariatric surgery improves the metabolic profile of morbidly obese patients with type 1 diabetes. Diabetes Care. 2014;37:e51-52.CrossRefPubMedPubMedCentral
19.
go back to reference Faucher P, Poitou C, Carette C, du Montcel ST, Barsamian C, Touati E, et al. Bariatric surgery in obese patients with type 1 diabetes: effects on weight loss and metabolic control. Obes Surg. 2016;26:2370–8.CrossRefPubMed Faucher P, Poitou C, Carette C, du Montcel ST, Barsamian C, Touati E, et al. Bariatric surgery in obese patients with type 1 diabetes: effects on weight loss and metabolic control. Obes Surg. 2016;26:2370–8.CrossRefPubMed
20.
go back to reference Lannoo M, Dillemans B, Van Nieuwenhove Y, Fieuws S, Mathieu C, Gillard P, et al. Bariatric surgery induces weight loss but does not improve glycemic control in patients with type 1 diabetes. Diabetes Care. 2014;37:e173-174.CrossRefPubMed Lannoo M, Dillemans B, Van Nieuwenhove Y, Fieuws S, Mathieu C, Gillard P, et al. Bariatric surgery induces weight loss but does not improve glycemic control in patients with type 1 diabetes. Diabetes Care. 2014;37:e173-174.CrossRefPubMed
21.
go back to reference Korakas E, Kountouri A, Raptis A, Kokkinos A, Lambadiari V. Bariatric surgery and type 1 diabetes: unanswered questions. Front Endocrinol (Lausanne). 2020;11: 525909.CrossRefPubMed Korakas E, Kountouri A, Raptis A, Kokkinos A, Lambadiari V. Bariatric surgery and type 1 diabetes: unanswered questions. Front Endocrinol (Lausanne). 2020;11: 525909.CrossRefPubMed
22.
go back to reference Mohammed N, Buckley A, Elsheikh M, Allum M, Suliman S, Al Hadad M, et al. Bariatric surgery in the treatment of patients with obesity and type 1 diabetes: a retrospective study of clinical data. Diabetes Obes Metab. 2021;23:1562–70.CrossRefPubMed Mohammed N, Buckley A, Elsheikh M, Allum M, Suliman S, Al Hadad M, et al. Bariatric surgery in the treatment of patients with obesity and type 1 diabetes: a retrospective study of clinical data. Diabetes Obes Metab. 2021;23:1562–70.CrossRefPubMed
23.
go back to reference Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954–62.CrossRefPubMed Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954–62.CrossRefPubMed
24.
go back to reference Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149–67.CrossRefPubMed Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149–67.CrossRefPubMed
26.
go back to reference Charbonnel B, Simon D, Dallongeville J, Bureau I, Dejager S, Levy-Bachelot L, et al. Direct medical costs of type 2 diabetes in France: an insurance claims database analysis. Pharmacoecon Open. 2018;2:209–19.CrossRefPubMed Charbonnel B, Simon D, Dallongeville J, Bureau I, Dejager S, Levy-Bachelot L, et al. Direct medical costs of type 2 diabetes in France: an insurance claims database analysis. Pharmacoecon Open. 2018;2:209–19.CrossRefPubMed
27.
go back to reference Debs T, Petrucciani N, Kassir R, Iannelli A, Amor IB, Gugenheim J. Trends of bariatric surgery in France during the last 10 years: analysis of 267,466 procedures from 2005–2014. Surg Obes Relat Dis. 2016;12:1602–9.CrossRefPubMed Debs T, Petrucciani N, Kassir R, Iannelli A, Amor IB, Gugenheim J. Trends of bariatric surgery in France during the last 10 years: analysis of 267,466 procedures from 2005–2014. Surg Obes Relat Dis. 2016;12:1602–9.CrossRefPubMed
28.
go back to reference Vilarrasa N, Rubio MA, Miñambres I, Flores L, Caixàs A, Ciudin A, et al. Long-term outcomes in patients with morbid obesity and type 1 diabetes undergoing bariatric surgery. Obes Surg. 2017;27:856–63.CrossRefPubMed Vilarrasa N, Rubio MA, Miñambres I, Flores L, Caixàs A, Ciudin A, et al. Long-term outcomes in patients with morbid obesity and type 1 diabetes undergoing bariatric surgery. Obes Surg. 2017;27:856–63.CrossRefPubMed
29.
go back to reference Giandalia A, Russo GT, Ruggeri P, Giancaterini A, Brun E, Cristofaro M, et al. The burden of obesity in type 1 diabetic subjects: a sex-specific analysis from the AMD annals initiative. J Clin Endocrinol Metab. 2023;108:e1224–35.CrossRefPubMedPubMedCentral Giandalia A, Russo GT, Ruggeri P, Giancaterini A, Brun E, Cristofaro M, et al. The burden of obesity in type 1 diabetic subjects: a sex-specific analysis from the AMD annals initiative. J Clin Endocrinol Metab. 2023;108:e1224–35.CrossRefPubMedPubMedCentral
30.
go back to reference Kermansaravi M, Valizadeh R, Jazi AD, Shahmiri SS, Martinez JAL, Mousavimaleki A, et al. Current status of metabolic/bariatric surgery in type 1 diabetes mellitus: an updated systematic review and meta-analysis. Obes Surg. 2022;32:1726–33.CrossRefPubMed Kermansaravi M, Valizadeh R, Jazi AD, Shahmiri SS, Martinez JAL, Mousavimaleki A, et al. Current status of metabolic/bariatric surgery in type 1 diabetes mellitus: an updated systematic review and meta-analysis. Obes Surg. 2022;32:1726–33.CrossRefPubMed
32.
go back to reference Fabron C, Laville M, Aron-Wisnewsky J, Disse E, Gatta-Cherifi B, Jacobi D, et al. Out-of-pocket expenses in households of people living with obesity in France. Obes Facts. 2023;16:606–13.CrossRefPubMedPubMedCentral Fabron C, Laville M, Aron-Wisnewsky J, Disse E, Gatta-Cherifi B, Jacobi D, et al. Out-of-pocket expenses in households of people living with obesity in France. Obes Facts. 2023;16:606–13.CrossRefPubMedPubMedCentral
Metadata
Title
Lights and Shadows of Bariatric Surgery: Insights from a Nationwide Administrative Database of People Living with Type 1 Diabetes and Obesity
Authors
Claire Carette
Claire Rives-Lange
Nicholas Shoung
Aurélie Phan
Elodie Torreton
Anne Dutour
Bruno Detournay
Sébastien Czernichow
Publication date
11-04-2025
Publisher
Springer Healthcare
Published in
Diabetes Therapy
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-025-01709-8

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar